Clinical outcomes of Impella 5+ in acute myocardial infarction-related cardiogenic shock: a retrospective single-center study
Frontiers in Cardiovascular Medicine · 21.07.2026 · 13
DOI: 10.3389/fcvm.2026.1840979 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 21.07.2026. Verfasst von Giulia Maj und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cardiothoracic and Vascular Anesthesia and Intensive Care, AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Temporary mechanical circulatory support (t-MCS) with Impella CP has recently attracted considerable interest as a therapeutic option for cardiogenic shock (CS) complicating acute myocardial infarction (AMI). In contrast, evidence regarding the use of the larger Impella 5+ (5.0/5.5) in this clinical setting remains limited. This single-centre retrospective study aimed to evaluate the clinical impact of Impella 5+ in patients with AMI-related cardiogenic shock (AMI-CS) Methods and results Between January 2022 and August 2024, 28 patients referred for AMI-CS were treated with Impella 5+. 11 patients were classified as SCAI C, 11 as SCAI D and 6 as SCAI E. On admission, median inotropic score was 10.5 and median left ventricular ejection fraction was 17.5%. 12 patients required concomitant ECMO support (ECPella). 19 patients were escalated from IABPM to Impella 5+. The median length of support was 8 days, 2 patients (7%) received the support for more than 30 days. 1 patient experienced a major bleeding complication. The overall survival during index hospitalization was 79%: 3 patients were bridged to a durable left ventricular assist device (LVAD) and 2 received heart transplantation (HTx).
Conclusions
Impella 5+ appears to be a safe and effective option in AMI-CS, associated with improved survival and a relatively low incidence of vascular and non-vascular complications. Its advanced features broaden the therapeutic potential of microaxial flow pumps in this high-risk setting.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiothoracic and Vascular Anesthesia and Intensive Care, AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
- Cardiology Department, IRCCS Policlinico Sant'Orsola, University Hospital of Bologna, Bologna, Italy.
- Cardiothoracic Intensive Care Department, Royal Papworth Hospital, Cambridge, United Kingdom.
- Interventional Cardiology Department and Cardiac Surgery Unit, AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
- Research and Innovation Department (DAIRI), University Hospital SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
- Kore University, Enna, Italy.
Zitieren
APA
Maj, G., Piermartiri, A., Querio, S., Bandini, M., Lombardi, M., Elia, E., Penpa, S., Mazzucco, R., Pappalardo, F., Cavozza, C., Gallo, A., Audo, A., Patti, G., & Secco, G. G. (2026). Clinical outcomes of Impella 5+ in acute myocardial infarction-related cardiogenic shock: a retrospective single-center study. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1840979
Vancouver
Maj G, Piermartiri A, Querio S, Bandini M, Lombardi M, Elia E, et al. Clinical outcomes of Impella 5+ in acute myocardial infarction-related cardiogenic shock: a retrospective single-center study. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1840979
BibTeX
@article{Maj2026,
author = {Maj, Giulia and Piermartiri, Alberto and Querio, Serena and Bandini, Marta and Lombardi, Marco and Elia, Edoardo and Penpa, Serena and Mazzucco, Riccardo and Pappalardo, Federico and Cavozza, Corrado and Gallo, Alina and Audo, Andrea and Patti, Giuseppe and Secco, Gioel Gabrio},
title = {Clinical outcomes of Impella 5+ in acute myocardial infarction-related cardiogenic shock: a retrospective single-center study},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1840979}
}
EUVIMED